Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.

The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.

Is US able to cope with Quademic 2025?

The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.

ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are

What are these quademic infections?

Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.

Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.

The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.

RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.

However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.

Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.

For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.

The US Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr., today launched a department-wide effort aimed at restoring American leadership in clinical trials and drug testing.

“Today, HHS launched a historic department-wide effort to strengthen America’s clinical research enterprise and ensure the next generation of medical breakthroughs is developed right here in the United States. Under President Trump’s leadership, we are accelerating innovation, expanding research capacity, and ensuring lifesaving discoveries are made in America,” Kennedy wrote in a post on social media platform X.

The Food and Drug Administration (FDA)-led pilot initiative, called Operation TrialBlazer comes at a time when China is gaining ground in the global biotechnology race.

Writing in a Fox News op-ed, Kennedy said, “America should continue to lead the world in clinical research and medical innovation. Instead, we are losing ground.”

He cited a recent study showing that China now conducts more early-stage clinical trials than the United States.

In 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. “Those trends should concern every American,” Kennedy said, stressing that “the future of medicine should be built in America.”

The coordinated department-wide effort aims to accelerate the development of lifesaving treatments in the United States and ensure that patients have access to some of the most innovative therapies in the world.

The initiative brings together multiple HHS divisions, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), and the Office of the Inspector General (OIG).

The effort aims to:

• Eliminate unnecessary delays
• Reduce redundant requirements
• Address regulatory ambiguity that can slow and disincentivize U.S.-based development
• Encourage the broader biomedical research ecosystem to do the same
• Foster a clinical research economy that delivers timely, safe, and effective medical products to support a healthy America

What Is Operation TrialBlazer?

According to the FDA, the initiative will help shorten development timelines by six to 12 months through a series of measures, including pairing drug developers with qualified academic centers and contract research organizations to prepare first-in-human trial applications.

The FDA has also issued draft guidance clarifying that, in many cases, one high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient to provide substantial evidence of effectiveness in support of a drug approval.

Other Programs To Accelerate Drug Research In The US

Read More: Powassan Virus: Deadly Tick-Borne Disease Spreading Across The US; Here's What You Need To Know

In addition to FDA's Operation TrialBlazer, the HHS has proposed initiatives by other divisions such as:

• NIH: Expanding support for well-powered clinical trials while advancing the use of AI, human cell-based models, real-world data, and practical trial tools to speed up therapy development without compromising scientific rigor.
• NCATS: Building on work that led to the first fully personalized CRISPR-based gene-editing treatment to accelerate therapies for rare diseases.
• National Cancer Institute (NCI): Working with cancer centers and researchers to streamline trial activation and improve enrollment in cancer studies.
• Office of the National Coordinator for Health Information Technology (ONC): Exploring ways to connect patients with clinical trials through electronic health records.
• ARPA-H: Advancing programs such as THRIVE and CATALYST to use AI and machine learning to improve trial design, predict safety, optimize dosing, and test multiple therapies simultaneously.
• HHS Office of Inspector General: Seeking public feedback on potential updates to regulations affecting incentives and participation in clinical trials.

Amid rising anemia in India, especially among pregnant women, the government has initiated the use of intravenous (IV) iron therapy to combat a condition that continues to be a significant public health challenge.

To date, four high-burden states have rolled out IV Ferric Carboxymaltose (FCM) therapy under the Anemia Mukt Bharat (AMB) initiative. Rajasthan was the first to launch the FCM Pink Drive in November 2025, followed by Andhra Pradesh (February 2026), Bihar (March 2026), and Uttar Pradesh (April 2026).

“The use of intravenous (IV) iron therapy has emerged as a scientifically sound alternative to restore iron levels and improve outcomes,” said Aradhana Patnaik, IAS, Additional Secretary and Mission Director (NHM). She added that it addresses moderate-to-severe anemia in pregnant women more effectively, particularly where oral iron is poorly tolerated or ineffective.

What Is Anemia ?

Anemia is a condition in which the number of red blood cells or their oxygen-carrying capacity is insufficient to meet the body's physiological needs.

Anemia during pregnancy is associated with postpartum hemorrhage, neural tube defects, low birth weight, premature births, stillbirths, and maternal and neonatal mortality. It can continue to affect women in the postpartum period and may worsen due to blood loss during and after delivery. This contributes to an intergenerational cycle of poor health and suboptimal growth.

According to the National Family Health Survey (NFHS-5), anemia remains a major public health issue in India, affecting:

• 52.2 per cent of pregnant women

• 60.6 per cent of lactating mothers

In an interview with HealthandMe, Prof. Dr. Sanjay Pandey, Head of the Department of Community and Family Medicine at AIIMS Patna, explained the rationale behind the therapy and its rollout in Bihar.

Why Are Women More Vulnerable to Anemia ?

Dr. Sanjay: Women are especially vulnerable to anemia because of menstrual blood loss, increased iron requirements during pregnancy, blood loss during childbirth, repeated pregnancies, poor dietary iron intake, infections, and certain genetic blood disorders.

What Is IV-FCM and How Does It Work?

Dr. Sanjay: Ferric Carboxymaltose (IV-FCM) is an injectable form of iron administered directly into the bloodstream. It is used to treat moderate-to-severe anemia when oral iron tablets are insufficient or poorly tolerated.

Unlike tablets, which depend on the gut to absorb iron slowly, a single IV-FCM infusion can deliver a full therapeutic dose in around 15 minutes, correcting hemoglobin levels within weeks.

How Is IV Iron Therapy Better Than Oral Iron?

Dr. Sanjay: One of the key advantages of FCM is that it can deliver up to 1,000 mg of iron in a single infusion lasting about 15 minutes, often resulting in a significant improvement in hemoglobin levels within two to four weeks.

The therapy reduces the need for

• multiple hospital visits,
• improves treatment compliance,
• causes fewer gastrointestinal side effects than oral iron,
• carries a lower risk of hypersensitivity reactions than older formulations such as iron dextran
• It also requires fewer infusions than iron sucrose.

When Is IV-FCM Recommended?

Dr. Sanjay: IV-FCM is recommended for:

• Pregnant Women: IV-FCM is recommended from the second trimester onwards, particularly in cases of moderate-to-severe anemia (Hb 5–9.9 g/dL). Studies indicate that FCM does not cross the placenta and does not negatively impact neonatal outcomes, including birth weight or fetal growth.

• Dose in Pregnancy: IV-FCM is given as an infusion of up to 1,000 mg in one sitting, mixed in 100 mL of normal saline over approximately 15 minutes. It should not be administered more than once a week.

How Safe Is IV Iron Therapy for Mother and Baby?

Dr. Sanjay: IV-FCM is considered safe and effective during pregnancy, with growing evidence supporting its use from the second trimester onwards.

• Maternal Outcomes: FCM corrects anemia rapidly. In the large Indian real-world PROMISE study involving 1,191 pregnant women, a single course of IV-FCM increased hemoglobin by approximately 2.8 g/dL within four weeks and by 3.6 g/dL among women with severe anemia , alongside significant improvement in iron stores.

• Neonatal Outcomes: FCM does not cross the placenta and has not been shown to adversely affect the baby. Studies report no negative impact on birth weight, five-minute Apgar scores, or fetal growth.

Are There Any Side Effects?

Dr. Sanjay: Women are typically observed for 30 minutes after infusion, and hemoglobin levels are reassessed after four weeks. IV-FCM is generally well tolerated. Mild side effects such as nausea, headache, dizziness, temporary increases in blood pressure and infusion-site reactions may occur.

How Bihar Is Expanding Access to IV-FCM Therapy

Dr. Sanjay: Bihar has procured around 2 lakh doses of IV-FCM. The rollout is expected to strengthen anemia management closer to communities through district hospitals and community health centers.

The program will improve access to advanced anemia treatment, particularly in rural areas where anemia prevalence among pregnant women exceeds 63 per cent.

India has achieved a significant milestone in its organ donation movement, with more than 5 lakh people pledging to donate their organs, according to the Ministry of Health and Family Welfare.

The achievement reflects growing public awareness of organ donation as a life-saving act that can offer hope and a second chance to patients awaiting transplants. It also marks a major step forward in the government's efforts to promote voluntary organ and tissue donation across the country.

Government Highlights Growing Awareness

In a statement, the Health Ministry said the milestone demonstrates increasing public participation and trust in the organ donation ecosystem.

"The Government of India remains steadfast in its commitment to bridging the gap between the demand and availability of organs and tissues through sustained awareness generation, enhanced institutional capacities, and strengthened transplantation systems."

The ministry added that efforts continue to ensure organ transplantation practices remain ethical, equitable, transparent, and patient-centric.

Also read: US Hospital Performs World's First HIV-to-HIV Lung Transplant, Offering Fresh Hope for HIV Patients

PM Modi's Appeals Boosted Organ Donation Movement

The organ donation campaign has gained momentum in recent years, aided by repeated appeals from Prime Minister Narendra Modi during his monthly radio program, Mann Ki Baat.

In the 131st episode, the Prime Minister highlighted the growing awareness around organ donation and its impact on healthcare.

"Awareness about organ donation is steadily rising in India these days. This is helping those who are in need of it. It is also strengthening medical research in the country. Many organizations and individuals are doing extraordinary work in this direction," the Prime Minister said.

Read More: AI Cannot Replace Doctors, It Can Only Complement, Says Dr Santosh Sivaranjani

Organ Transplants Quadruple In A Decade

According to the latest government data, India has witnessed a fourfold increase in organ transplants over the last decade.

• 2013: Fewer than 5,000 organ transplants
• 2025: Nearly 20,000 organ transplants

Online Portal Simplifies Registration

To make the process more accessible, the government launched an Aadhaar-based online organ donation pledge portal in 2023.

The platform, notto.abdm.gov.in, allows citizens to register their organ donation pledge securely and transparently.

Officials say the portal has significantly streamlined the registration process and encouraged greater public participation.

How To Become An Organ Donor

According to the All India Institute of Medical Science (AIIMS), you can choose to be a donor while you are alive, or your family can give their permission after you pass away.

The Organ Retrieval Banking Organization (ORBO) helps coordinate this entire process. If you want to donate your organs after you die, you can pledge to be a donor now.

Steps to pledge organ donation:

1. Fill Out the Donor Form

• Obtain the organ donor form from ORBO or register online through the national portal.

• The form must be signed by two witnesses, including one close family member.

• Send the completed form to ORBO or complete the online registration process.

• Registered donors receive a donor card along with a registration number.

• Share your decision with family members and keep your donor card accessible so your wishes are known.